-transparent.png){kind=logo}
The effects of a zinc phosphate suspension of a long-acting, reportedly selective somatostatin analog, Des-Ala1,Gly2 [His4,5,D-Try]-somatostatin (100 micrograms/kg) on postprandial plasma glucose, glucagon, xylose and triglyceride levels were evaluated in alloxan diabetic dogs. Compared to the analog in aqueous solution, the zinc phosphate suspension had a more gradual onset of action in suppressing plasma glucose and xylose levels but a similar onset of action on suppression of plasma triglyceride and glucagon responses. On all these responses, the zinc suspension had a duration of action (greater than 6 hrs) at least three times as long as the aqueous solution. We conclude that such a somatostatin analog in zinc phosphate suspension may have a sufficient duration of action to be useful as an adjunct to insulin in the treatment of diabetes mellitus.
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
March 1987,
The American journal of clinical nutrition,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
May 1979,
Diabetes,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
January 1988,
Peptides,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
August 1978,
FEBS letters,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
July 1979,
Diabetologia,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
September 1977,
FEBS letters,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
October 1990,
The American journal of the medical sciences,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
July 1980,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
July 1993,
Canadian journal of physiology and pharmacology,
C Martin, and
B Wallum, and
B Krom, and
L Hall, and
J Gerich
September 1975,
Metabolism: clinical and experimental,
